If you have been reading about reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
According to the Ukrainian Air Force, Russia attacked Ukraine's infrastructure with 35 Iranian kamikaze drones, 30 of which were said to have been shot down. 23 of the drones attacked Kyiv (according to the city officials, 18 of them were shot down). An infrastructure facility was damaged, leaving three areas in Kyiv without power. Energy shortages caused interruptions in heat and water supply. Mykolaiv and Kherson regions were also attacked. Building of Kherson Oblast State Administration was partially destroyed.
== Regulatory status == PRP is not regulated by the FDA because, like certain other human tissue and blood products, it is exempted from the traditional regulatory pathways; any use of PRP in a clinical setting is therefore considered "off label". The medical devices used to prepare PRP, however, are subject to FDA clearance.
A 2022 study concluded that the practice of rinsing uncooked chicken actually increases the risk of pathogen transfer through the splashing of water droplets, with factors such as faucet height, flow type, and surface stiffness affecting the risk of cross-contamination. The most common bacterial foodborne pathogens are:
Applications using this early discover were limited due to naturally low concentrations of this anti-haemophilic factor in blood and plasma and volume constraints in the circulatory system. In 1954, the Government wished to establish a site for increased production of blood products. This followed on from the importance of blood in therapeutic medicine, the need for blood products during the Second World War (particularly the use of albumin) and the formation on 26 September 1946 of the National Blood Transfusion Service. It had also been discovered that a second form of haemophilia (Haemophilia B) existed, which was treatable with blood protein called Factor IX. An agreement was reached between the Government, MRC and the Lister Institute and the Blood Products Laboratory was established with funding from the Ministry of Health. Enlarged facilities for plasma fractionation and freeze-drying were established. During the 1970s and early 1980s it became apparent that Factor VIII products produced at the BPL site (and other products from other companies) may have infected haemophiliacs with life-threatening viruses. Bigger risks to the patient population arose from U.S.imported products, a practice required since the UK was not self-sufficient in plasma products. In 1991 it was renamed the Bio Products Laboratory to reflect the internal market in the National Health Service and in 1993 it became part of the National Blood Authority. BPL began cross-charging NHS hospitals for its products and limited competition in the international blood plasma market was permitted.
== Gene location of IDDM == Genome-wide linkage analysis could be used for identification in susceptibility genes of insulin-dependent (type I) diabetes mellitus (IDDM). This analysis verifies that eighteen different genome regions are predisposed to insulin-dependent (type I) diabetes mellitus(IDDM). There are 18 different symbols of genome region, which is labeled from IDDM1 to IDDM18. The MHC HLA gene (IDDM1) and the insulin gene INS (IDDM2) are the major genetic candidates in the development of insulin-dependent (type I) diabetes mellitus(IDDM), which are located on the chromosome 6p21.3 and chromosome 11p15 respectively. IDDM3, IDDM4, IDDM5 IDDM7 reside in chromosome 15q26, chromosome 11q13, chromosome 6q25 and 2q31 respectively.IDDM11 (insulin-dependent diabetes mellitus 11) is one of the susceptibility genes for IDDM which locates on chromosome 14q24.3-q31. This loci is identified by linkage to D14S67 marker via a sibling-pair linkage analysis Based on the previous study, the biological behavior of IDDM11is different to HLA region genes so that IDDM11 is less predisposing to HLA. Moreover, IDDM11 has more involvement on the families that are less predisposing to HLA, while IDDM11 has less involvement on the families that are more predisposing to HLA. The rest of susceptibility genes locus in insulin-dependent (type I) diabetes mellitus (IDDM)are shown in table 1. Table 1 The locus for susceptibility genes for IDDM.
Sources: en.wikipedia.org
== Electrochemical Carbon nanotube filter == Carbon nanotubes have gained much attention for its use as wastewater and water filter. Carbon nanotube’s mechanical, electrical and chemical properties made it unique and an ideal candidate for research since 1990. Carbon nanotube combined with electrochemistry proved to be the best method for water and wastewater purification. Electrochemistry helps in reducing the fouling rate of the CNT. In case of CNT based ultra-filters modified with electrochemistry, helps in reducing the energy by two folds comparing to an unmodified CNT based filters. Thus electrochemical carbon nanotubes have been developed due to the advanced studies in nanotechnology and electrochemistry. Here the electrochemical activity of the CNT is exploited. Very first electrochemical CNT was developed by P.J.Britto etal and the results were first recognized in 1996. An electrochemical CNT filter contains electrodes and CNT in a systematic setup such that the electrodes can attract the wastes that clog the CNT based on its charges, thus resulting in high efficiency of filtering and extension of the lifetime of the CNT in the process. The electrochemical carbon nanotubes can be easily used for removing amino group based dyes from wastewater. Chen etal first reported the absorption of dyes to the CNT walls by strong covalent bonds. These electrochemical CNT can be typically used for filtering, and recycling wastewater.
== Investigation == Between March and June 2022, unusually high infant mortality rates occurred at a neonatal nursing unit in the Ramón Castillo Neonatal Hospital in Córdoba, Argentina. A series of investigations initially pointed to a hospital-acquired infection or malpractice. The provincial government then intervened at the Ramón Castillo Neonatal Hospital after these reports of healthy babies dying without cause. Prosecutor Raúl Garzón labelled the case as "enormously grave" but initially insisted that they could have been either cases of malpractice or hospital-acquired infections, and no accusations were made. Nonetheless, Garzón ordered a search warrant on the hospital and relieved twenty employees from their duties. Police and prosecutors began to suspect that there had been foul play when no more deaths occurred after the suspension of those twenty employees. On the same day that the hospital was searched, authorities suspended the head of the hospital. The investigation was prompted by a doctor who refused to sign the death certificates of two healthy babies who died on the same day in June 2022; allegedly the two last babies to die from an external cause (murder). As the search warrant was served, the prosecution asked for the exhumation of the remains of the deceased babies, whose autopsies showed abnormal levels of potassium, which medical investigators attributed to being deliberately injected into the babies, as said levels of potassium are not normally produced by the body.
The speed of sound in helium is nearly three times the speed of sound in air. Because the natural resonance frequency of a gas-filled cavity is proportional to the speed of sound in the gas, when helium is inhaled, a corresponding increase occurs in the resonant frequencies of the vocal tract, which is the amplifier of vocal sound. This increase in the resonant frequency of the amplifier (the vocal tract) gives increased amplification to the high-frequency components of the sound wave produced by the direct vibration of the vocal folds, compared to the case when the voice box is filled with air. When a person speaks after inhaling helium gas, the muscles that control the voice box still move in the same way as when the voice box is filled with air; therefore the fundamental frequency (sometimes called pitch) produced by direct vibration of the vocal folds does not change. However, the high-frequency-preferred amplification causes a change in timbre of the amplified sound, resulting in a reedy, duck-like vocal quality. The opposite effect, lowering resonant frequencies, can be obtained by inhaling a dense gas such as sulfur hexafluoride or xenon.
In blood serum, the content of nitrogenous substances such as urea and creatinine (uremia or azotemia) and phosphate (hyperphosphatemia). The increased phosphate concentration is the result of the reduced glomerular filtration rate. Among other things, fibroblast growth factor 23 (FGF-23) is involved here, which is more sensitive than the phosphate level in the event of an incipient disorder. The potassium content is usually reduced (hypokalemia), but can also be increased—the reverse is true for the sodium content. If the cause of the kidney disease lies in the renal corpuscles, albumin deficiency (hypalbuminemia) and excess cholesterol (hypercholesterolemia) also occur. The determination of cystatin C is not evaluated for cats, this protein can also be elevated in cats with hyperthyroidism or with glucocorticoids and drop sharply for several hours after food intake. Recent studies suggest that symmetric dimethylarginine (SDMA) is a suitable marker for renal function in cats. The SDMA concentration in serum shows close correlations with the glomerular filtration rate and the creatinine concentration. It can already detect a 40% loss of kidney function, i.e. before there is an increase in creatinine in the blood. The most sensitive method of kidney function diagnostics is the direct determination of the glomerular filtration rate via the clearance, which is already reduced in chronic kidney disease before azotemia occurs. Various substances have been evaluated for cats, the most practical being creatinine and iohexol.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.